Crinetics

Crinetics Pharmaceuticals develops novel therapeutics for rare endocrine diseases and tumors, with key products including Paltusotine and Atumelnant.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2018
Stage of Initial Investment
Series B
Initial Investment Year
2018
Crinetics Portco Hover Image